ReviewPolymer science & technology (Washington, D.C.)2026
Engineering Polymeric Nano-PROTAC for Targeted Protein Degradation and Cancer Therapy.
Review in Polymer science & technology (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatiotemporal Nanotransformers for Antitumoral Orchestration of Protein Homeostasis.Polymer science & technology (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted protein degradation (TPD) has revolutionized the therapeutic landscape of cancer therapy. TPD aids in avoiding cellular malfunction by recruiting the protein of interest (POI) into intracellular degradation machinery. The proteolysis-targeting chimeras (PROTACs) degradation hijacks the protein's disposal system and co-opts ubiquitin E3 ligase to degrade disease-associated proteins. Numerous PROTACs have come to the forefront in cancer therapy, and several are in clinical trials. PROTACs are on the verge of U.S. Food and Drug Administration (FDA) approval. However, the low bioavailability, inadequate delivery, non-specific biodistribution, and systemic toxicity are impairing their clinical potential. Nano-PROTACs have implications for precisely targeting intractable proteins. This review provides insights into the realm of cellular mechanisms of nano-PROTACs, especially for targeting bromodomain-containing protein 4 (BRD4), programmed death-ligand 1 (PD-L1), programmed cell death protein 1 (PD-1), and indoleamine 2,3-dioxygenase (IDO). How stimuli-responsive linkages are introduced in polymeric nanoparticles to aid the controlled release of PROTACs is discussed. We provide a glimpse of how advanced polymer- and peptide-based nano-PROTACs degradation is being combined with photoimmunotherapy, radiation therapy, and chemotherapy to broaden the impact of cancer therapy. Opportunities and challenges of current strategies are discussed to preclude major limitations in clinical translation. The integration of nano-PROTACs with potentially curative therapeutic modalities may broaden the clinical performance of PROTACs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.